Publicaciones en colaboración con investigadores/as de Universitat Pompeu Fabra (5)

2024

  1. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

    Clinical Genitourinary Cancer, Vol. 22, Núm. 5

2019

  1. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

    OncoImmunology, Vol. 8, Núm. 7

2015

  1. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 91, Núm. 1, pp. 133-139

  2. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137

2013

  1. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 87, Núm. 4, pp. 690-696